SCHEDULE 13G/A: BlackRock Discloses 1% Stake in Lineage Cell Therapeutics, Subsidiary Holds Over 5%

BlackRock, Inc. has filed an amended Schedule 13G disclosing a 1.0% beneficial ownership in Lineage Cell Therapeutics Inc. common stock, while also noting that a subsidiary, BlackRock Institutional Trust Company, National Association, holds 5% or more.

Summary

• BlackRock, Inc. reported beneficial ownership of 2,234,545 shares of Lineage Cell Therapeutics Inc. common stock.
• This represents 1.0% of the total outstanding common stock of Lineage Cell Therapeutics Inc. for the aggregated reporting business units of BlackRock, Inc.
• BlackRock, Inc. holds sole voting power and sole dispositive power over all 2,234,545 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, filed under Rule 13d-1(b).
• A subsidiary, BlackRock Institutional Trust Company, National Association, beneficially owns 5% or greater of the outstanding shares of Lineage Cell Therapeutics Inc., with this ownership disaggregated from the main BlackRock, Inc. reporting units' aggregate.

Sentiment

Score: 6

Explanation: The disclosure of a 1.0% stake by BlackRock's aggregated reporting units, coupled with a subsidiary holding 5% or more, indicates a notable institutional presence, which is generally positive for a company. However, the 1.0% itself is not a large stake.

Positives

• The presence of a major institutional investor like BlackRock, Inc. holding a stake, even if small for the parent entity's aggregated units, can be viewed as a vote of confidence in Lineage Cell Therapeutics Inc.
• The disclosure that a BlackRock subsidiary holds 5% or more indicates a more substantial investment by a BlackRock entity in the company.

Negatives

• The 1.0% stake reported by BlackRock, Inc. for its aggregated reporting units is a relatively small percentage, which might not signal strong conviction from the broader BlackRock group's directly reported holdings.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

Schedule 13G filings are routine disclosures by large institutional investors like BlackRock, indicating their passive investment stakes (typically less than 20% and not for control purposes). BlackRock's diverse portfolio often includes small stakes in numerous companies, and the disaggregation of ownership by different internal units is standard practice for large asset managers to comply with SEC reporting rules.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, specifically BlackRock's stake and its subsidiary's larger holding, which can influence investor perception and confidence.

Key Dates

Keywords

BlackRock, Lineage Cell Therapeutics, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake